SCNN1A
Epithelial sodium channel subunit alpha
As of the edition of 20 October 2026, SCNN1A (epithelial sodium channel subunit alpha, UniProt P37088) has 4 drugs tested at it and 7 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P37088
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 3
- Disease areas
- Heart and blood vessels; Lungs and airways; Digestive system; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Hormones; Nervous system
- Registered trials of its drugs
- 43
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Amiloride | Marketed | Phase 4 | none listed |
| Idrevloride | Went quiet | Phase 2 | none listed |
| Cofirasersen | Stopped | Phase 2 | none listed |
| Triamterene | Marketed | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Undetermined | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Gilead Sciences | Route A |
| Akcea Therapeutics | Route A |
| Parion Sciences | Route A |
The other 4 companies at SCNN1A
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at SCNN1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.